Research Topics
Species | Eunice L KwakSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancerEunice L Kwak
Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
N Engl J Med 363:1693-703. 2010..We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALK tyrosine kinase...
Hereditary colorectal cancer syndromes: an overviewEunice L Kwak
Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
Clin Colorectal Cancer 6:340-4. 2007....- Targeted agents: the rules of combinationEunice L Kwak
Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
Clin Cancer Res 13:5232-7. 2007..An overview of the MTAs that have emerged as Food and Drug Administration-approved drugs is presented, along with a framework for the consideration of how MTAs can best be combined to maximize therapeutic effect... - The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancerEunice Kwak
Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
Oncologist 16:1498-507. 2011..Results of large, randomized trials of these agents may help to determine their potential for the treatment of NSCLC... 
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancerJason E Faris
Department of Medical Oncology, Massachusetts General Hospital Cancer Center, POB 221, Boston, MA 02114, USA
Invest New Drugs 30:1614-20. 2012..MKC-1 is an orally available cell cycle inhibitor with downstream targets that include tubulin and the importin-β family. We conducted an open-label Phase II study with MKC-1 in patients with advanced pancreatic cancer...- Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancerNils D Arvold
Harvard Radiation Oncology Program, Boston, Massachusetts, USA
Cancer 118:3026-35. 2012..Neoadjuvant chemotherapy before chemoradiation therapy (CRT) may improve outcomes for patients with locally advanced pancreatic cancer, but optimal management remains controversial, and prior reports have limited follow-up... - Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisAlice T Shaw
Massachusetts General Hospital Cancer Center, Boston, MA, USA
Lancet Oncol 12:1004-12. 2011.... - Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKAlice T Shaw
Department of Pathology, Massachusetts General Hospital, Warren 501c, 55 Fruit St, Boston, MA 02114, USA
J Clin Oncol 27:4247-53. 2009..To aid in identification and treatment of these patients, we examined the clinical characteristics and treatment outcomes of patients who had NSCLC with and without EML4-ALK... - Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?Ioannis T Konstantinidis
Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
Ann Surg 257:731-6. 2013..Our aim was to compare the survival of patients undergoing an R1 resection with those having LA tumors and to explore the prognostic significance of a 1-mm surgical margin... - Phase 1/2 study of everolimus in advanced hepatocellular carcinomaAndrew X Zhu
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
Cancer 117:5094-102. 2011..The phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway plays a critical role in the pathogenesis of hepatocellular carcinoma (HCC). We performed a single-arm, phase 1/2 study of everolimus in patients with advanced HCC... - Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapyNils D Arvold
Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA, USA
Int J Radiat Oncol Biol Phys 83:e337-43. 2012..The role of adjuvant radiotherapy (RT) in these patients has not been characterized... - Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximabRaymond C Wadlow
Massachusetts General Hospital, Boston, Massachusetts, USA
Oncologist 17:14. 2012..We performed a single-arm phase II trial of panitumumab in patients with KRAS wild-type metastatic colorectal cancer that had progressed on prior cetuximab... - ROS1 rearrangements define a unique molecular class of lung cancersKristin Bergethon
Massachusetts General Hospital, Boston, MA 02114 2696, USA
J Clin Oncol 30:863-70. 2012..Because little is known about these tumors, we examined the clinical characteristics and treatment outcomes of patients with NSCLC with ROS1 rearrangement... - Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyAndrew X Zhu
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
Lancet Oncol 11:48-54. 2010.... - Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapyLisa A Kachnic
Department of Radiation Oncology, Boston Medical Center, Boston, MA 02118, USA
Int J Radiat Oncol Biol Phys 82:153-8. 2012..Chemoradiation for anal cancer yields effective tumor control, but is associated with significant acute toxicity. We report our multi-institutional experience using dose-painted IMRT (DP-IMRT)... - Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the headTheodore S Hong
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Int J Radiat Oncol Biol Phys 79:151-7. 2011..To evaluate the safety of 1 week of chemoradiation with proton beam therapy and capecitabine followed by early surgery... - Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal CancerBrian M Wolpin
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
Oncologist 18:377-8. 2013..2% vs. 29.4%) and longer OS times (10.6 vs. 3.7 months). Conclusions. The oral combination of tivozanib and everolimus was well tolerated, with stable disease achieved in 50% of patients with refractory, metastatic colorectal cancer... - MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinibJochen K Lennerz
Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
J Clin Oncol 29:4803-10. 2011..We examined a GEC cohort with follow-up and reported the clinical response of four additional patients with MET-amplified tumors to the small molecule inhibitor crizotinib as part of an expanded phase I cohort study... - Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicineDora Dias-Santagata
Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
EMBO Mol Med 2:146-58. 2010..This work therefore establishes a platform for real-time targeted genotyping that can be widely adopted. We expect that efforts like this one will play an increasingly important role in cancer management... - Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancerMichael S Lee
Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
Oncologist 18:281-7. 2013..To determine the efficacy and toxicity of weekly neoadjuvant cetuximab combined with irinotecan, cisplatin, and radiation therapy in patients with locally advanced esophageal or gastroesophageal junction cancer... - Crizotinib in ALK-rearranged inflammatory myofibroblastic tumorJames E Butrynski
Dana Farber Cancer Institute, Boston, MA 02115, USA
N Engl J Med 363:1727-33. 2010..Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.)... - MDM2 promoter polymorphism and pancreatic cancer risk and prognosisKofi Asomaning
Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA
Clin Cancer Res 14:4010-5. 2008..We hypothesized that the G allele is also associated with increased risk and worse outcome in pancreatic cancer... - Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancerMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 25:4787-92. 2007..We evaluated an oral regimen of capecitabine and erlotinib in patients with advanced pancreatic cancer who had experienced treatment failure with standard first-line therapy with gemcitabine... - Isolation of rare circulating tumour cells in cancer patients by microchip technologySunitha Nagrath
Surgical Services and BioMEMS Resource Center, Massachusetts General Hospital, Harvard Medical School, and Shriners Hospital for Children, Boston, Massachusetts 02114, USA
Nature 450:1235-9. 2007..It has broad implications in advancing both cancer biology research and clinical cancer management, including the detection, diagnosis and monitoring of cancer... - Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II studyAndrew X Zhu
Division of Hematology Oncology, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Oncol 27:3027-35. 2009..To assess the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) and explore biomarkers for sunitinib response... - Targeted therapies with chemoradiation in esophageal cancer: development and future directionsTheodore S Hong
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Semin Radiat Oncol 23:31-7. 2013..Additionally, more recently identified targets of interest in esophagogastric cancers, including c-MET, heat shock protein 90, and Sonic hedgehog, are discussed in the context of chemoradiation... - Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibEunice L Kwak
Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA
Proc Natl Acad Sci U S A 102:7665-70. 2005..Our findings suggest that one of these, HKI-272, may prove highly effective in the treatment of EGFR-mutant NSCLCs, including tumors that have become resistant to gefitinib or erlotinib... - Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomasEunice L Kwak
Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA
Clin Cancer Res 12:4283-7. 2006..Given recent reports of TKI-responsive cases of esophageal and pancreatic cancer, this study was designed to determine the prevalence of EGFR mutations in these gastrointestinal cancers...